EPO and bronchopulmonary dysplasia: While retrospective studies have demonstrated a potential benefit of erythropoietin in reducing BPD in preterm infants, a meta-analysis consisting of 17 RCTs showed no difference in the incidence of BPD between infants receiving EPO and placebo (264–266).